Hetero Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs. | ![]() Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. | ![]() WuXi AppTec WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies. | Qilu Pharmaceutical Qilu Pharmaceutical (齐鲁制药) is a company that develops, manufactures, and markets generic drugs and active pharmaceutical ingredients (APIs). | ![]() Intas Pharmaceuticals Intas is one of the leading global pharmaceutical formulation development, manufacturing, and marketing companies. | |
Founding Date | Founding Date 1993 | Founding Date 1923 | Founding Date 2000 | Founding Date 1958 | Founding Date 1996 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Hyderabad, IN HQ Norwest, AU Sao Paulo, BR Beijing, CN Nanjing Shi, CN Nanjing Shi, CN Bogotá, CO see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Shanghai, CN HQ Beijing, CN Changzhou, CN Chengdu, CN Guangzhou, CN Nantong, CN Shanghai, CN see more | Locations Jinan Shi, CN HQ Boston, US | Locations Ahmedabad, IN HQ Durham, US |
Employees | Employees 7,0042% increase | Employees 14,754 | Employees 39,414 | Employees 39,0008% increase | Employees 17,4211% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 20.8 b | Valuation ($) 20.7 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥1.9t (FY, 2025) | Revenue (est.) ¥37.6b (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥150.1b (FY, 2025) | Cost of goods ¥23b (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit ¥1.8t (FY, 2025) | Gross profit ¥16b (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ¥50.7b (FY, 2025) | Net income ¥9.6b (FY, 2024) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Scientists and Researchers | Scientists and Researchers 1 k (Jan, 2021) | Scientists and Researchers N/A | Scientists and Researchers 38 k (H1, 2023) | Scientists and Researchers N/A | Scientists and Researchers N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 902.6m | Total funding raised N/A | Total funding raised $ 295.2m |
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
View companyWuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies.
View companyQilu Pharmaceutical (齐鲁制药) is a company that develops, manufactures, and markets generic drugs and active pharmaceutical ingredients (APIs).
View companyIntas is one of the leading global pharmaceutical formulation development, manufacturing, and marketing companies.
View company